Stockscreener 앱 받기
0.7702
2.68%
0.0201
시장 영업 전:
.80
0.0298
+3.87%
전일 마감가:
$0.7501
열려 있는:
$0.75
하루 거래량:
44,337
Relative Volume:
0.47
시가총액:
$32.37M
수익:
-
순이익/손실:
$-31.37M
주가수익비율:
-0.5356
EPS:
-1.438
순현금흐름:
$-4.23M
1주 성능:
-2.27%
1개월 성능:
-2.75%
6개월 성능:
-39.35%
1년 성능:
-43.78%
1일 변동 폭
$0.75
$0.7816
1주일 범위
$0.74
$0.81
52주 변동 폭
$0.60
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
명칭
Mira Pharmaceuticals Inc
전화
813-369-5150
주소
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.7702 | 29.84M | 0 | -31.37M | -4.23M | -1.438 |
LLY
Lilly Eli Co
|
1,156.73 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
265.85 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.42 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
147.76 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.06 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Mira Pharmaceuticals Inc 주식(MIRA)의 최신 뉴스
MIRA (MIRA) Financial Results: The Company Lists Its Latest Available Figures in the Latest Session; Investor Response: Shares Fall 3.16% in the Latest ReadingSegment Revenue Breakdown - vinanet.vn
MIRA Q2 2026 Earnings: -$0.03 EPS Reinforces Clinical-Stage, Pre-Revenue StatusBanking Earnings Report - vinanet.vn
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire
MIRA Pharmaceuticals Edges Higher: Stock Gains 1.37% as Shares Hold Key Support LevelDouble Bottom - vinanet.vn
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss of -$0.06 Per Share Highlights Cost DisciplineUpward Estimate Revision - vinanet.vn
Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MIRA Q3 2025 Earnings: Narrower-than-Expected Loss Drives 9.36% Stock GainSegment Revenue Breakdown - vinanet.vn
Form 8K Mira Pharmaceuticals Inc For: 6 August By Investing.com - Investing.com South Africa
MIRA's obesity candidate shows rapid absorption in 7-day dog study - stocktitan.net
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 - Asianet Newsable
MIRA Reports Positive Preclinical Results for Obesity Candidate SKNY-1 - TipRanks
NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView
12 Health Care Stocks Moving In Monday's After-Market SessionEnsysce Biosciences (NASDAQ:ENSC), TransC - Benzinga
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline in Pre-Revenue Stage - vinanet.vn
MIRA Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRA - TradingView
MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice - TipRanks
Mira advances MIRA-55 and SKNY-1 - bioworld.com
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies - GlobeNewswire
MIRA Q3 2025 Earnings: EPS Beat on Narrower Loss Highlights Cost DisciplinePost-Announcement Reaction - vinanet.vn
MIRA Q3 2025 Earnings: Narrower-than-Expected Loss Drives Positive Surprise Despite Stock DeclineEBITDA Margin Trends - vinanet.vn
Mira Pharmaceuticals Inc (MIRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mira Pharmaceuticals Inc (MIRA) Cash Flow - TradingKey
Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mira Pharmaceuticals Inc (MIRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MIRA Q3 2025 Earnings: EPS Surprise of 26.47% on Narrowed Loss Despite No RevenueEarnings Miss Alert - vinanet.vn
MIRA|Mira Pharmaceuticals Inc|Price:0.764|Chg%:-0.025 - TradingKey
Mira Pharmaceuticals Inc (MIRA) Income Statement - TradingKey
TradingKey - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – DUS:K6S - TradingView
MIRA|Mira Pharmaceuticals Inc|Price:0.882|Chg%:+0.000 - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – LSX:A3EQWL - TradingView
Mira Pharmaceuticals Inc (MIRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MIRA Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRA) - TradingView
Mergers & Acquisitions - Modern Healthcare
MIRA Q3 2025 Earnings: Narrower-than-expected Loss Amid Pre-Revenue PhaseConsensus Miss Rate - vinanet.vn
Andriy Mushak Net Worth (2026) - GuruFocus
Why Is MIRA (NASDAQ:MIRA) Non-Opioid Program in Focus? - Kalkine Media
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire
MIRA Q3 2025 Earnings: Narrower-than-Expected Net Loss Highlights Cost ManagementPositive Surprise Momentum - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
MIRA Pharmaceuticals (NASDAQ:MIRA) Advances Pain Program - Kalkine Media
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 - Investing.com
MIRA Pharmaceuticals announces positive preclinical results for MIRA-55 - TipRanks
Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies - Moomoo
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 By Investing.com - Investing.com Canada
MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55 - Stock Titan
Experimental MIRA-55 pill shows brain and liver reach in pain studies - Stock Titan
MIRA Q3 2025 Earnings: Positive EPS Surprise Fails to Lift SharesEarnings Revision Report - DonanımHaber
Mira reports results on optimized oral formulation of SKNY-1 - BioWorld News
Mira Pharmaceuticals Inc (MIRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.79%
0.61%
자본화:
|
볼륨(24시간):